A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS)

European Journal of Immunology

Volumn 44, Issue 7, 2014, Pages 2096-2110

  Negm, Ola H ^a,b   Mannsperger, Heiko A ^c,e   Mcdermott, Elizabeth M ^d   Drewe, Elizabeth ^d   Powell, Richard J ^a   Todd, Ian ^a   Fairclough, Lucy C ^a   Tighe, Patrick J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MANSOURA UNIVERSITY   (Egypt)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e MetaSystems GmbH   (Germany)

Author keywords

Autoinflammation; Protein microarray; Signalome; TNF receptor 1; TRAPS

Indexed keywords

AUTOINFLAMMATION; PROTEIN MICROARRAY; SIGNALOME; TNF RECEPTOR 1; TRAPS;

CELL LINE, TUMOR; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; MUTATION; NF-KAPPA B; PROTEIN ARRAY ANALYSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904396578     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201344328     Document Type: Article

References (40)

1. McDermott, M. F., Aksentijevich, I., Galon, J., McDermott, E. M., Ogunkolade, B. W., Centola, M., Mansfield, E. et al., Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999. 97: 133-144.
2. Sarrauste de Menthiere, C., Terriere, S., Pugnere, D., Ruiz, M., Demaille, J. and Touitou, I., INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res. 2003. 31: 282-285.
3. Huggins, M. L., Radford, P. M., McIntosh, R. S., Bainbridge, S. E., Dickinson, P., Draper-Morgan, K. A., Tighe, P. J. et al., Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum. 2004. 50: 2651-2659.
4. Todd, I., Radford, P. M., Draper-Morgan, K. A., McIntosh, R., Bainbridge, S., Dickinson, P., Jamhawi, L. et al., Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 2004. 113: 65-79.
5. Rebelo, S. L., Bainbridge, S. E., Amel-Kashipaz, M. R., Radford, P. M., Powell, R. J., Todd, I. and Tighe, P. J., Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum. 2006. 54: 2674-2687.
6. Todd, I., Radford, P. M., Daffa, N., Bainbridge, S. E., Powell, R. J. and Tighe, P. J., Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum. 2007. 56: 2765-2773.
7. Yousaf, N., Gould, D. J., Aganna, E., Hammond, L., Mirakian, R. M., Turner, M. D., Hitman, G. A. et al., Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-kappaB activation. Arthritis Rheum. 2005. 52: 2906-2916.
8. Rebelo, S. L., Amel-Kashipaz, M. R., Radford, P. M., Bainbridge, S. E., Fiets, R., Fang, J., McDermott, E. M. et al., Novel markers of inflammation identified in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) by transcriptomic analysis of effects of TRAPS-associated tumor necrosis factor receptor type I mutations in an endothelial cell line. Arthritis Rheum. 2009. 60: 269-280.
9. Dickie, L. J., Aziz, A. M., Savic, S., Lucherini, O. M., Cantarini, L., Geiler, J., Wong, C. H. et al., Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann. Rheum. Dis. 2012. 71: 2035-2043.
10. Bachetti, T., Chiesa, S., Castagnola, P., Bani, D., Di Zanni, E., Omenetti, A., D'Osualdo, A. et al., Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann. Rheum. Dis. 2013. 72: 1044-1052.
11. Simon, A., Park, H., Maddipati, R., Lobito, A. A., Bulua, A. C., Jackson, A. J., Chae, J. J. et al., Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc. Natl. Acad. Sci. U.S.A. 2010. 107: 9801-9806.
12. Lobito, A. A., Kimberley, F. C., Muppidi, J. R., Komarow, H., Jackson, A. J., Hull, K. M., Kastner, D. L. et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006. 108: 1320-1327.
13. Bulua, A. C., Simon, A., Maddipati, R., Pelletier, M., Park, H., Kim, K. Y., Sack, M. N. et al., Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J. Exp. Med. 2011. 208: 519-533.
14. Schutze, S., Tchikov, V. and Schneider-Brachert, W., Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat. Rev. Mol. Cell. Biol. 2008. 9: 655-662.
15. Schneider-Brachert, W., Tchikov, V., Neumeyer, J., Jakob, M., Winoto-Morbach, S., Held-Feindt, J., Heinrich, M. et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004. 21: 415-428.
16. Zhou, Z., Connell, M. C. and MacEwan, D. J., TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. Cell Signal. 2007. 19: 1238-1248.
17. Adam-Klages, S., Schwandner, R., Adam, D., Kreder, D., Bernardo, K. and Kronke, M., Distinct adapter proteins mediate acid versus neutral sphingomyelinase activation through the p55 receptor for tumor necrosis factor. J. Leukoc. Biol. 1998. 63: 678-682.
18. Pincheira, R., Castro, A. F., Ozes, O. N., Idumalla, P. S. and Donner, D. B., Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signaling pathways that regulate transcription factor activity. J. Immunol. 2008. 181: 1288-1298.
19. Miscia, S., Marchisio, M., Grilli, A., Di Valerio, V., Centurione, L., Sabatino, G., Garaci, F., et al. Tumor necrosis factor alpha (TNF-alpha) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells. Cell Growth Diff.: Mol. Biol. J. American Assoc. Cancer Res. 2002. 13: 13-18.
20. MacEwan, D. J., TNF receptor subtype signalling: differences and cellular consequences. Cell Signal. 2002. 14: 477-492.
21. Nedjai, B., Hitman, G. A., Yousaf, N., Chernajovsky, Y., Stjernberg-Salmela, S., Pettersson, T., Ranki, A. et al., Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008. 58: 273-283.
22. Siebert, S., Fielding, C. A., Williams, B. D. and Brennan, P., Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF-kappaB activation due to decreased surface expression. FEBS Lett. 2005. 579: 5193-5198.
23. Kamata, H., Honda, S., Maeda, S., Chang, L., Hirata, H. and Karin, M., Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005. 120: 649-661.
24. D'Osualdo, A., Ferlito, F., Prigione, I., Obici, L., Meini, A., Zulian, F., Pontillo, A. et al., Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum. 2006. 54: 998-1008.
25. Nedjai, B., Hitman, G. A., Quillinan, N., Coughlan, R. J., Church, L., McDermott, M. F. and Turner, M. D., Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2009. 60: 619-625.
26. Ter Haar, N., Lachmann, H., Ozen, S., Woo, P., Uziel, Y., Modesto, C., Kone-Paut, I. et al., Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann. Rheum. Dis. 2013. 72: 678-685.
27. Nowlan, M. L., Drewe, E., Bulsara, H., Esposito, N., Robins, R. A., Tighe, P. J., Powell, R. J. et al., Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatol. (Oxford) 2006. 45: 31-37.
28. Vaitla, P. M., Radford, P. M., Tighe, P. J., Powell, R. J., McDermott, E. M., Todd, I. and Drewe, E., Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: Assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum. 2011. 63: 1151-1155.
29. Moll, M. and Kuemmerle-Deschner, J. B., Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin. Immunol. 2013. 147: 242-275.
30. Murakami, M. and Hirano, T., A four-step model for the IL-6 amplifier, a regulator of chronic inflammations in tissue-specific MHC class II-associated autoimmune diseases. Frontiers Immunol. 2011. 2: 22.
31. Ogura, H., Murakami, M., Okuyama, Y., Tsuruoka, M., Kitabayashi, C., Kanamoto, M., Nishihara, M. et al., Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008. 29: 628-636.
32. Quillinan, N., Mohammad, A., Mannion, G., O'Keeffe, D., Bergin, D., Coughlan, R., McDermott, M. F. et al., Imaging evidence for persistent subclinical fasciitis and arthritis in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) between febrile attacks. Ann. Rheum. Dis. 2010. 69: 1408-1409.
33. Hull, K. M., Wong, K., Wood, G. M., Chu, W. S. and Kastner, D. L., Monocytic fasciitis: a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum. 2002. 46: 2189-2194.
34. Sims, J. E. and Smith, D. E., The IL-1 family: regulators of immunity. Nature Rev. Immunol. 2010. 10: 89-102.
35. Hu, D. N., Chen, M., Zhang, D. Y., Ye, F., McCormick, S. A. and Chan, C. C., Interleukin-1beta increases baseline expression and secretion of interleukin-6 by human uveal melanocytes in vitro via the p38 MAPK/NF-kappaB pathway. Invest. Ophthalmol. Vis. Sci. 2011. 52: 3767-3774.
36. You, M., Flick, L. M., Yu, D. and Feng, G. S., Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J. Exp. Med. 2001. 193: 101-110.
37. Ohmori, S., Hino, R., Nakamura, M. and Tokura, Y., Heparin serves as a natural stimulant of the inflammasome and exacerbates the symptoms of tumor necrosis factor receptor-associated periodic syndrome (TRAPS). J. Dermatol. Sci. 2012. 66: 82-84.
38. Cheon, H., Yang, J. and Stark, G. R., The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J. Interferon Cytokine Res. 2011. 31: 33-40.
39. Yang, J., Liao, X., Agarwal, M. K., Barnes, L., Auron, P. E. and Stark, G. R., Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Develop. 2007. 21: 1396-1408.
40. Mannsperger, H. A., Gade, S., Henjes, F., Beissbarth, T. and Korf, U., RPPanalyzer: Analysis of reverse-phase protein array data. Bioinformatics 2010. 26: 2202-2203.